Hypopharyngeal Neoplasms clinical trials
The registry lists 148 studies for Hypopharyngeal Neoplasms across more than 10 countries. 45 are recruiting or about to start. 22 of them are mainly about Hypopharyngeal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Hypopharyngeal Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (7) · Mayo Clinic (5) · Emory University (4) · Groupe Oncologie Radiotherapie Tete et Cou (4) · Fudan University (4) · Eye & ENT Hospital of Fudan University (4) · Memorial Sloan Kettering Cancer Center (4)
What is being tested here
Drugs under test in Hypopharyngeal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cisplatin | 5 | 3 | 14 |
| Docetaxel | 3 | 3 | 7 |
| Toripalimab | 3 | 0 | 3 |
| Cetuximab | 2 | 2 | 8 |
| Fluorouracil | 1 | 3 | 6 |
| Celecoxib | 1 | 0 | 4 |
| Pembrolizumab | 1 | 0 | 3 |
| Ipatasertib | 1 | 0 | 2 |
| Ficerafusp alfa | 1 | 0 | 1 |
| Cabozantinib | 1 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 5 open · Antimitotic agents 3 open · Antimetabolites 3 open · Tyrosine kinase inhibitors (TKIs) 2 open
Coming up
14studies finish main data collection within a year
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Dec 2026Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck · Ohio State University Comprehensive Cancer Center
- Dec 2026Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy · University Hospital Freiburg
- Jan 2027BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · National Cancer Institute (NCI)
- Jan 2027Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer · NRG Oncology
- Mar 2027Salvage Surgery in Recurrent Hypopharyngeal Carcinoma: an Observational Single-institutional Study From 1998 · Fondazione IRCCS Policlinico San Matteo di Pavia
- Apr 2027Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients · M.D. Anderson Cancer Center
- Jun 2027Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · National Cancer Institute (NCI)
- Jun 2027Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" · M.D. Anderson Cancer Center
- Jul 2027Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · National Cancer Institute (NCI)
- Aug 2027Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen · The First Affiliated Hospital of Xiamen University
Who these studies take
Of the 38 Hypopharyngeal Neoplasms studies recruiting now, 23 (61%) set no upper age limit and 8 (21%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (5%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 35 (92%) | 35 (92%) |
| 30 | 37 (97%) | 37 (97%) |
| 40 | 37 (97%) | 37 (97%) |
| 50 | 37 (97%) | 37 (97%) |
| 65 | 38 (100%) | 38 (100%) |
| 75 | 36 (95%) | 36 (95%) |
| 85 | 29 (76%) | 29 (76%) |
Across all 148 studies, recruiting or not: 19% stop at 75 or younger and 1% at 65; 6% take children; 1% are for women only and 1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 148. Browse all 148 → or search them.
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingNCT06589804Phase 31 country
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 21 country
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingNCT05172245Phase 12 countries
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/21 country
- Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07926906Not applicable1 country
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/24 countries
- PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck CancerRecruitingNCT06914999Early Phase 11 country
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/21 country
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal VolunteersRecruitingNCT009004191 country
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07156227Phase 11 country
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07898124Phase 11 country
- Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck CancerRecruitingNCT030101501 country
- Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck CancersRecruitingNCT07857655Phase 41 country
- Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 21 country
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryRecruitingNCT02734537Phase 21 country
- Thermotherapy for Head and Neck Cancer PatientsRecruitingNCT07690618Phase 11 country
- A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous LesionsRecruitingNCT075325381 country
- Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerRecruitingNCT06532279Phase 21 country
- Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationRecruitingNCT06662058Not applicable1 country
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"RecruitingNCT01365169Not applicable1 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaRecruitingNCT06706401Phase 31 country
- TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 11 country
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingNCT07063212Phase 21 country
- Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 21 country
- Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and NeckRecruitingNCT01473784Not applicable1 country
- The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell CarcinomaRecruitingNCT05494190Not applicable1 country
- Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal CarcinomaRecruitingNCT07248956Phase 21 country
- Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)RecruitingNCT049086961 country
- Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy RegimenNot yet recruitingNCT07137039Phase 21 country
- The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal CancerRecruitingNCT058940701 country
- Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal CarcinomaNot yet recruitingNCT06957938Phase 31 country
- Special Care Patterns for Elderly HNSCC Patients Undergoing RadiotherapyRecruitingNCT053376315 countries
- SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and HypopharynxRecruitingNCT06611137Phase 21 country
- Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal CancerNot yet recruitingNCT06554028Phase 21 country
- Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal CancerRecruitingNCT05860335Phase 21 country
- Submental Flap for the Reconstruction of HypopharyngectomyRecruitingNCT06161779Not applicable1 country
- Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal CancerRecruitingNCT06039631Phase 21 country
- Immunological Function After Radiation With Either Proton or Photon TherapyRecruitingNCT060166991 country
- Immune Biomarker Study for Head and Neck CancerRecruitingNCT053752661 country
- Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal CarcinomaRecruitingNCT05420597Phase 21 country
- Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal CarcinomaRecruitingNCT04995120Phase 21 country
- Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCCNot yet recruitingNCT04624308Phase 21 country
- Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 TrialRecruitingNCT04502641Phase 31 country
- Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal CancerNot yet recruitingNCT03367884Not applicable1 country
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 21 country
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/31 country
- Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer PatientsActive, not recruitingNCT02253238Not applicable1 country
- Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and NeckCompletedNCT02113878Phase 11 country
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingNCT04533750Phase 11 country